Allostatic load dynamics, Alzheimer's disease biomarkers, and progression in individuals with mild cognitive impairment: findings from the Alzheimer's Disease Neuroimaging Initiative.
Juliana N Souza-Talarico, Yelena Perkhounkova, Maria Hein, Jihye Lee, Marco Hefti, Shireen Sindi
{"title":"Allostatic load dynamics, Alzheimer's disease biomarkers, and progression in individuals with mild cognitive impairment: findings from the Alzheimer's Disease Neuroimaging Initiative.","authors":"Juliana N Souza-Talarico, Yelena Perkhounkova, Maria Hein, Jihye Lee, Marco Hefti, Shireen Sindi","doi":"10.1002/dad2.70140","DOIUrl":null,"url":null,"abstract":"<p><p>Allostatic load (AL), reflecting chronic stress, is linked to cognitive decline, but its role in the Alzheimer's disease (AD) continuum needs further study. We examined the relationship between AL, progression from mild cognitive impairment (MCI) to mild dementia due to AD, and AD biomarkers. We analyzed 385 MCI individuals over 36 months using Alzheimer's Disease Neuroimaging Initiative (ADNI) data. AL index (ALI) changes over 12 months were calculated using plasma neuroendocrine, immunological, and metabolic markers. AD biomarkers included plasma amyloid beta 42 (Aβ42), cerebrospinal fluid (CSF) Aβ1-42, tau, and hippocampus volume. A one-point ALI increase was associated with MCI conversion odds by 15%. ALI increased in those progressing to mild dementia due to AD and decreased in MCI stable participants. ALI increases were linked to high CSF tau, plasma Aβ42, and low CSF Aβ1-42, moderated by age, <i>APOE</i> ε4, and baseline tau levels. AL may interact with age and genetic risk, impacting AD biomarkers and MCI progression.</p><p><strong>Highlights: </strong>ALI increase raises MCI to AD conversion odds by 15%.ALI increases in those progressing to AD and decreases in stable participants.Higher ALI was linked to high CSF tau, plasma Aβ42, and low CSF Aβ1-42These associations were moderated by age, <i>APOE</i> ε4 status, and baseline CSF tau.</p>","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"17 3","pages":"e70140"},"PeriodicalIF":4.0000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12213454/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/dad2.70140","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Allostatic load (AL), reflecting chronic stress, is linked to cognitive decline, but its role in the Alzheimer's disease (AD) continuum needs further study. We examined the relationship between AL, progression from mild cognitive impairment (MCI) to mild dementia due to AD, and AD biomarkers. We analyzed 385 MCI individuals over 36 months using Alzheimer's Disease Neuroimaging Initiative (ADNI) data. AL index (ALI) changes over 12 months were calculated using plasma neuroendocrine, immunological, and metabolic markers. AD biomarkers included plasma amyloid beta 42 (Aβ42), cerebrospinal fluid (CSF) Aβ1-42, tau, and hippocampus volume. A one-point ALI increase was associated with MCI conversion odds by 15%. ALI increased in those progressing to mild dementia due to AD and decreased in MCI stable participants. ALI increases were linked to high CSF tau, plasma Aβ42, and low CSF Aβ1-42, moderated by age, APOE ε4, and baseline tau levels. AL may interact with age and genetic risk, impacting AD biomarkers and MCI progression.
Highlights: ALI increase raises MCI to AD conversion odds by 15%.ALI increases in those progressing to AD and decreases in stable participants.Higher ALI was linked to high CSF tau, plasma Aβ42, and low CSF Aβ1-42These associations were moderated by age, APOE ε4 status, and baseline CSF tau.
期刊介绍:
Alzheimer''s & Dementia: Diagnosis, Assessment & Disease Monitoring (DADM) is an open access, peer-reviewed, journal from the Alzheimer''s Association® that will publish new research that reports the discovery, development and validation of instruments, technologies, algorithms, and innovative processes. Papers will cover a range of topics interested in the early and accurate detection of individuals with memory complaints and/or among asymptomatic individuals at elevated risk for various forms of memory disorders. The expectation for published papers will be to translate fundamental knowledge about the neurobiology of the disease into practical reports that describe both the conceptual and methodological aspects of the submitted scientific inquiry. Published topics will explore the development of biomarkers, surrogate markers, and conceptual/methodological challenges. Publication priority will be given to papers that 1) describe putative surrogate markers that accurately track disease progression, 2) biomarkers that fulfill international regulatory requirements, 3) reports from large, well-characterized population-based cohorts that comprise the heterogeneity and diversity of asymptomatic individuals and 4) algorithmic development that considers multi-marker arrays (e.g., integrated-omics, genetics, biofluids, imaging, etc.) and advanced computational analytics and technologies.